Project Grant HT94252510095
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The University of Queensland (UQ) received a $676,323 Project Grant award from the Defense Health Agency through the Military Medical Research and Development program. The grant will fund UQ's research project "A NOVEL BIOMARKER OF ASTROCYTE DYSFUNCTION AND GLUTAMATE DYSREGULATION IN BRAIN AND SPINAL CORD IN ALS" from August 1, 2023 to July 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This $749,995 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of gene therapies for the targeted degradation of the TDP-43 protein to treat Amyotrophic Lateral Sclerosis (ALS) at Macquarie University in Australia. The project aims to advance therapeutic approaches for this neurodegenerative disease. Macquarie University, a non-profit educational institution, will conduct the research over a...
The federal Project Grant award of $1,103,084 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding the development of a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The prime awardee, Arizona State University's Division Orspa, is leading the research effort. The project will run from November 1, 2024 to October 31, 2026.
As a sub-award under this grant, Georgetown University is...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The Department of the Army Medical Command awarded Macquarie University $999,748.80 under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025.
The grant funding will support Macquarie University's project "QUINOLINONES AS A NOVEL THERAPEUTIC STRATEGY IN ALS" which aims to investigate medical solutions for amyotrophic lateral sclerosis (ALS) through the development of quinolinone compounds. The...
The University of Denver was awarded a $877,397 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "SYNTHETIC PROTEIN MIMETICS-BASED SPECIFIC TARGETING AND DEGRADATION OF TDP-43 AGGREGATION ASSOCIATED WITH ALS". This 2-year grant, with an award date of March 1, 2024 and a completion date of February 28, 2026, will support the university's research efforts to develop new treatments for...
The Defense Health Agency awarded The Trustees of the University of Pennsylvania $750,484 under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The project aims to identify plasma biomarkers in amyotrophic lateral sclerosis (ALS) and related disorders that can classify clinical subtypes and provide prognostic information. Specifically, the University of Pennsylvania will evaluate plasma P-tau181 and neurofilament light...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....